ClinicalTrials.gg
TerminatedNCT00687544Updated Apr 6, 2017Results posted

Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

A Phase 4 interventional study of Peginterferon alfa-2b (SCH 054031) and Ribavirin (SCH 018908) in Hepatitis C, Chronic, Hepacivirus and HIV Infections, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
34th of 39
11 · median 99
Started
2005
with 7 others
Phase 4
10 of 40
none open now
Registered
21st of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2005, is one of 10 in phase 4, and was the 21st registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

In this study, adult Indonesian subjects with human immunodeficiency virus (HIV) coinfected with chronic hepatitis C (CHC) will be given peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) combination therapy. The efficacy rate (sustained virologic response, end of treatment virologic response, and sustained biochemical response), the subject morbidity rate as caused by other opportunistic infection (eg, bacterial pneumonia, tuberculosis, and other bacterial infection), and the safety and tolerability of this combination therapy will be examined.

03

Conditions studied

  • Hepatitis C, Chronic
  • Hepacivirus
  • HIV Infections

Keywords

  • HIV
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated chronic with HCV-RNA positive in plasma.
  • Must have finished the detoxification phase of a drug rehabilitation program and abstained for at least 6 weeks from using abused substance (alcohol, I.V. drugs and inhaled drugs) before starting therapy.
  • Liver transaminases ( [ALT]) 1.5-fold above the .
  • Controlled infection with a viral load \<10,000 copies/mL and a CD4 cell (T-cell) count >200 x 10\^6 cells/L, in response to a stable antiretroviral treatment (ART) or without ART if it is not required.
  • Compensated liver disease with protocol-specified minimum hematologic, biochemical, and serologic criteria at the Entry visit.
  • Alpha-fetoprotein value within normal limits obtained within one year prior to entry. Results above the upper limit of normal but \<=50 ng/mL require both of the following: Alpha-fetoprotein value \<=50 ng/mL obtained within 3 months prior to entry in the study and Ultrasound obtained within 3 months prior to entry in the study or that is negative for evidence of hepatocellular carcinoma.
  • Liver (optional) within 12 months prior to study entry with a pathology report confirming that the histologic diagnosis is consistent with chronic hepatitis.
  • Women of must be using an acceptable method of or be surgically sterilized.
  • Reconfirmation that sexually active males must be practicing acceptable methods of contraception during the treatment period and for 6 months after discontinuation of therapy.
  • Subjects must be free of any diseases other than hepatitis or HIV infection that would interfere with study evaluations.

Exclusion criteria

Exclusion Criteria:

  • Suspected to interferon, PEG-interferon, or ribavirin.
  • therapy using didanosine (ddI) and stavudine (d4T) in their HIV medications, due to the potentiality of the resulting lactic acidosis.
  • Participation in any other clinical trial within 30 days of entry to this protocol.
  • Treatment with any drug within 30 days of entry to this protocol.
  • Subjects with organ transplants other than cornea and hair transplant.
  • Any cause for the liver disease based on subject history and (where applicable) other than chronic , including but not limited to coinfection with virus (HBV); hemochromatosis (iron deposition >2+ in liver parenchyma); alpha-1 antitrypsin deficiency; Wilson's disease; hepatitis; alcoholic liver disease; obesity-induced liver disease.
  • Hemophilia or any other condition that would prevent the subject from having a liver biopsy, including anticoagulant therapy.
  • Hemoglobinopathies (eg, Thalassemia)
  • Evidence of advanced liver disease such as history or presence of ascites, bleeding varices, and encephalopathy.
  • Any known preexisting medical condition that could interfere with the subject's participation in and completion of the protocol such as preexisting psychiatric condition, especially severe depression, or a history of severe psychiatric disorder.
  • Significant cardiovascular dysfunction within the past 6 months (eg, angina, congestive heart failure, recent myocardial infarction, severe hypertension, or significant arrhythmia). Subjects with (ECG) showing abnormalities.
  • Poorly controlled diabetes mellitus.
  • Chronic pulmonary disease (eg, ).
  • Immunologically mediated disease.
  • Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of .
  • Clinical gout.
  • Clinically significant retinal abnormalities.
  • Alcohol consumption of >20 gr/day.
  • Women who are pregnant or nursing.
  • Subjects who have not observed the designated for any of the prohibited medications.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    PEG-IFN + RBV

    PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV

    Biological: Peginterferon alfa-2b (SCH 054031) · Drug: Ribavirin (SCH 018908)

Interventions

  • Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.

    Also known as: PegIntron

  • Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is \<65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is \>85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.

    Also known as: Rebetol

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Sustained Virologic Response (SVR)

    Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SVR was defined as plasma HCV RNA level below lower level of quanitation at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.

    Time frame: Week 48 or Week 72 (depending on duration of treatment)

  2. Number of Participants Who Achieved Virologic Response (VR)

    Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. The study was terminated due to low enrollment. This analysis was not performed.

    Time frame: 24 Weeks or 48 Weeks (depending on duration of treatment, which was either 24 or 48 weeks)

  3. Number of Participants Who Achieved Sustained Biochemical Response (SBR)

    Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SBR was defined as the presence of normal alanine aminotransferase (ALT) values at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.

    Time frame: Week 48 or Week 72 (depending on duration of treatment, which was either 24 or 48 weeks)

Secondary outcomes

  1. Number of Participants Experiencing Opportunistic Infection

    The study was terminated due to low enrollment. This analysis was not performed.

    Time frame: Throughout the study (up to 72 weeks)

  2. Number of Participants Who Died

    Time frame: Throughout the study (up to 72 weeks)

  3. Number of Participants Experiencing Adverse Events

    An adverse event was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, which did not necessarily have a causal relationship with the treatment.

    Time frame: Throughout the study (up to 72 weeks)

07

Results

Posted Jan 30, 2012
Limitations and caveats
The study was terminated early due to low enrollment. The primary and secondary outcomes were not evaluated. A formal safety analysis was not performed for the 11 participants enrolled in the study.

Participant flow

Participant flow — Overall Study
MilestonePEG-IFN + RBV
Started11
Completed0
Not completed11

Outcome measures

PrimaryNumber of Participants Who Achieved Sustained Virologic Response (SVR)

Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SVR was defined as plasma HCV RNA level below lower level of quanitation at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.

Time frame:
Week 48 or Week 72 (depending on duration of treatment)

No measurements were reported for this outcome.

PrimaryNumber of Participants Who Achieved Virologic Response (VR)

Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. The study was terminated due to low enrollment. This analysis was not performed.

Time frame:
24 Weeks or 48 Weeks (depending on duration of treatment, which was either 24 or 48 weeks)

No measurements were reported for this outcome.

SecondaryNumber of Participants Experiencing Opportunistic Infection

The study was terminated due to low enrollment. This analysis was not performed.

Time frame:
Throughout the study (up to 72 weeks)

No measurements were reported for this outcome.

PrimaryNumber of Participants Who Achieved Sustained Biochemical Response (SBR)

Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SBR was defined as the presence of normal alanine aminotransferase (ALT) values at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.

Time frame:
Week 48 or Week 72 (depending on duration of treatment, which was either 24 or 48 weeks)

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Died
Time frame:
Throughout the study (up to 72 weeks)
Reported as:
Number · participants
Number of Participants Who Died
participantsPEG-IFN + RBV
Number of Participants Who Died0
SecondaryNumber of Participants Experiencing Adverse Events

An adverse event was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, which did not necessarily have a causal relationship with the treatment.

Time frame:
Throughout the study (up to 72 weeks)
Reported as:
Number · participants
Number of Participants Experiencing Adverse Events
participantsPEG-IFN + RBV
Number of Participants Experiencing Adverse Events10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-IFN + RBV—1/11 (9.1%)10/11 (90.9%)
Most frequent serious events
Most frequent serious events
EventPEG-IFN + RBV
AnemiaBlood and lymphatic system disorders1/11
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPEG-IFN + RBV
Influenza like illnessGeneral disorders7/11
GastritisGastrointestinal disorders6/11
AnemiaBlood and lymphatic system disorders2/11
DiarrheaGastrointestinal disorders2/11
Skin infectionInfections and infestations2/11
DizzinessNervous system disorders2/11
DepressionPsychiatric disorders2/11
AnxietyPsychiatric disorders2/11
InsomniaPsychiatric disorders2/11
VertigoEar and labyrinth disorders1/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PEG-IFN + RBV
<=18 years0
Between 18 and 65 years11
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IFN + RBV
Female0
Male11
Region of Enrollment
Region of Enrollment(participants)PEG-IFN + RBV
Indonesia11
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
Start
Dec 2005
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Jan 30, 2012
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00687544
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Dec 2005
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Jan 30, 2012
Last update
Apr 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion